SCHEMBL16202082

SCHEMBL16202082

CCO/N=C(\C)c1ccc(C)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PTBP1 P26599 1/20 0.41
PPARG P37231 3/20 0.40
PPARA Q07869 3/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HPGD P15428 3/20 0.39
PKM P14618 1/20 0.39
ALDH1A1 P00352 1/20 0.39
NPFFR2 Q9Y5X5 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
GAA P10253 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16202057 0.86 PPARG (0.51) LMNASMN1; SMN2PTBP1PPARGPPARA
SCHEMBL17219269 0.83 HSP90AA1 (0.47) LMNASMN1; SMN2PTBP1PPARGPPARA
SCHEMBL15851107 0.83 HSP90AA1 (0.47) LMNASMN1; SMN2PTBP1PPARGPPARA
SCHEMBL16202081 0.83 NPFFR2 (0.41) LMNASMN1; SMN2HPGDALDH1A1NPFFR2
SCHEMBL17217588 0.80 NPC1 (0.48) LMNASMN1; SMN2PTBP1PPARGPPARA
SCHEMBL15851161 0.80 NPC1 (0.48) LMNASMN1; SMN2PTBP1PPARGPPARA
SCHEMBL13683674 0.77 SMN1; SMN2 (0.52) LMNASMN1; SMN2PTBP1PPARGPPARA
SCHEMBL7941464 0.76 PPARG (0.38) LMNASMN1; SMN2PTBP1PPARGPPARA
SCHEMBL7941466 0.76 PPARG (0.38) LMNASMN1; SMN2PTBP1PPARGPPARA
SCHEMBL26714161 0.75 L3MBTL1 (0.49) LMNASMN1; SMN2PPARGPPARAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2016-09-01 US disclosed
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-26 US disclosed
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi BASF SE (DE) 2016-05-26 US disclosed
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-05 US disclosed
US-9271501-B2 Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors BASF SE (DE) 2016-03-01 US disclosed
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI SNX1, DPM1, SNU13 LMNA 4479/4885SMN1; SMN2 2653/4885PTBP1 2494/4885
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI DPM1, CROCC, SNX1 LMNA 4670/4885SMN1; SMN2 3486/4885PTBP1 2745/4885
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi DPM1, CROCC, SNX1 LMNA 4670/4885SMN1; SMN2 3486/4885PTBP1 2745/4885
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB LMNA 3613/4885SMN1; SMN2 2724/4885PTBP1 2774/4885
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB LMNA 3613/4885SMN1; SMN2 2724/4885PTBP1 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.